Doctor of Oncology, Peking University Health Science Center; Associate Chief Physician; currently serving as Deputy Director of the Second Ward, Department of Thoracic Oncology, Beijing Cancer Hospital. Specialty: Long-term dedication to the medical treatment and clinical teaching of thoracic tumors, with a focus on comprehensive treatment strategies for primary lung cancer, encompassing chemotherapy, targeted therapy, and immunotherapy. As a core member of the department's clinical and research team, deeply involved in the application and execution of multiple ongoing research projects. Extensively participated in over 150 clinical trials of new drugs, including immunotherapy, and accumulated clinical experience from over a thousand cases of targeted therapy and immunotherapy for lung cancer, possessing rich clinical practice experience and solid research capabilities. From August 2017 to July 2018, conducted a one-year visiting scholar research at the Fred Hutchinson Cancer Research Center in the United States, focusing on the frontier field of epigenetics, with a particular emphasis on exploring the inhibitory effects and mechanisms of PRMT-5 inhibitors on tumor proliferation in small cell lung cancer cell lines and PDX mouse models. Holds multiple academic positions: Vice Chairman of the Science Education Committee, Beijing Cancer Prevention and Treatment Association; Standing Committee Member of the Molecular Targeted Therapy Professional Committee, Beijing Society of Chronic Diseases; Member of the Pharmacy Professional Committee, China Medical Women's Association; Member of the Lung Tumor Integrated Rehabilitation Professional Committee, Chinese Anti-Cancer Association; actively participates in academic exchanges and discipline construction across various professional platforms.